Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ...
Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from ...
Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...
MedPage Today on MSN
AI-triggered nephrology consult fails to prevent acute kidney injury in trial
Increases in serum creatinine similar to patients who received usual care ...
UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal ...
Five women in Rajasthan seeking help after alleged postpartum kidney failure have drawn attention to postpartum acute kidney ...
Morning Overview on MSN
A common blood-pressure pill mixed with a routine antibiotic can trigger kidney injury
Patients who take a calcium-channel blocker for high blood pressure and then receive a prescription for clarithromycin, one ...
Serious damage to short-term kidney function—known as acute kidney injury, or AKI—can be fatal and also increase the risk of irreversible chronic kidney disease. It can be triggered by stressors ...
Five women from Rajasthan's Kota suffering from postpartum kidney failure have refused to continue dialysis and intensified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results